Mechanisms of Triglyceride Metabolism in Patients with Bile Acid Diarrhea

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2016 Aug 30

PMID 27570415

Citations 8

Authors

Nidhi Midhu Sagar

Michael McFarlane

Chuka Nwokolo

Karna Dev Bardhan

Ramesh Pulendran Arasaradnam

Affiliations

Soon will be listed here.

Abstract

Bile acids (BAs) are essential for the absorption of lipids. BA synthesis is inhibited through intestinal farnesoid X receptor (FXR) activity. BA sequestration is known to influence BA metabolism and control serum lipid concentrations. Animal data has demonstrated a regulatory role for the FXR in triglyceride metabolism. FXR inhibits hepatic lipogenesis by inhibiting the expression of sterol regulatory element binding protein 1c via small heterodimer primer activity. Conversely, FXR promotes free fatty acids oxidation by inducing the expression of peroxisome proliferator-activated receptor α. FXR can reduce the expression of microsomal triglyceride transfer protein, which regulates the assembly of very low-density lipoproteins (VLDL). FXR activation in turn promotes the clearance of circulating triglycerides by inducing apolipoprotein C-II, very low-density lipoproteins receptor (VLDL-R) and the expression of Syndecan-1 together with the repression of apolipoprotein C-III, which increases lipoprotein lipase activity. There is currently minimal clinical data on triglyceride metabolism in patients with bile acid diarrhoea (BAD). Emerging data suggests that a third of patients with BAD have hypertriglyceridemia. Further research is required to establish the risk of hypertriglyceridaemia in patients with BAD and elicit the mechanisms behind this, allowing for targeted treatment.

Citing Articles

The bsh1 gene of Lactobacillus plantarum AR113 ameliorates liver injury in colitis mice.

Shao J, Xia Y, Wang G, Xiong Z, Yang Y, Song X NPJ Sci Food. 2025; 9(1):22.

PMID: 39934175 PMC: 11814123. DOI: 10.1038/s41538-025-00373-3.

Characterisation of the Plasma and Faecal Metabolomes in Participants with Functional Gastrointestinal Disorders.

Fraser K, James S, Young W, Gearry R, Heenan P, Keenan J Int J Mol Sci. 2025; 25(24.

PMID: 39769229 PMC: 11677738. DOI: 10.3390/ijms252413465.

Bile acid diarrhoea and metabolic changes after cholecystectomy: a prospective case-control study.

Farrugia A, Williams N, Khan S, Arasaradnam R BMC Gastroenterol. 2024; 24(1):282.

PMID: 39174936 PMC: 11340142. DOI: 10.1186/s12876-024-03368-8.

Assessing causal associations of bile acids with obesity indicators: A Mendelian randomization study.

Huang C, Xu S, Chen R, Ding Y, Fu Q, He B Medicine (Baltimore). 2024; 103(25):e38610.

PMID: 38905395 PMC: 11191951. DOI: 10.1097/MD.0000000000038610.

Tailoring FXR Modulators for Intestinal Specificity: Recent Progress and Insights.

Morrison A, Elgendy B Molecules. 2024; 29(9.

PMID: 38731514 PMC: 11085346. DOI: 10.3390/molecules29092022.

References

Calkin A, Tontonoz P . Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol. 2012; 13(4):213-24. PMC: 3597092. DOI: 10.1038/nrm3312. View

Stellaard F, Sackmann M, Sauerbruch T, Paumgartner G . Simultaneous determination of cholic acid and chenodeoxycholic acid pool sizes and fractional turnover rates in human serum using 13C-labeled bile acids. J Lipid Res. 1984; 25(12):1313-9. View

Torra I, Claudel T, Duval C, Kosykh V, Fruchart J, Staels B . Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol. 2003; 17(2):259-72. DOI: 10.1210/me.2002-0120. View

Hakala K, Vuoristo M, Luukkonen P, Jarvinen H, Miettinen T . Impaired absorption of cholesterol and bile acids in patients with an ileoanal anastomosis. Gut. 1998; 41(6):771-7. PMC: 1891592. DOI: 10.1136/gut.41.6.771. View

Hirokane H, Nakahara M, Tachibana S, Shimizu M, Sato R . Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J Biol Chem. 2004; 279(44):45685-92. DOI: 10.1074/jbc.M404255200. View

Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, Fruchart J . Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology. 2003; 125(2):544-55. DOI: 10.1016/s0016-5085(03)00896-5. View

Insull Jr W . Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J. 2006; 99(3):257-73. DOI: 10.1097/01.smj.0000208120.73327.db. View

Beil U, Crouse J, Einarsson K, Grundy S . Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density-lipoprotein triglycerides. Metabolism. 1982; 31(5):438-44. DOI: 10.1016/0026-0495(82)90231-1. View

Jiao Y, Lu Y, Li X . Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis. Acta Pharmacol Sin. 2014; 36(1):44-50. PMC: 4571315. DOI: 10.1038/aps.2014.116. View

10.

Bisschop P, Bandsma R, Stellaard F, ter Harmsel A, Meijer A, Sauerwein H . Low-fat, high-carbohydrate and high-fat, low-carbohydrate diets decrease primary bile acid synthesis in humans. Am J Clin Nutr. 2004; 79(4):570-6. DOI: 10.1093/ajcn/79.4.570. View

11.

Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J . Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998; 98(19):2088-93. DOI: 10.1161/01.cir.98.19.2088. View

12.

Bertolotti M, Spady D, Dietschy J . Regulation of hepatic cholesterol metabolism in the rat in vivo: effect of a synthetic fat-free diet on sterol synthesis and low-density lipoprotein transport. Biochim Biophys Acta. 1995; 1255(3):293-300. DOI: 10.1016/0005-2760(94)00245-t. View

13.

Camilleri M . Advances in understanding of bile acid diarrhea. Expert Rev Gastroenterol Hepatol. 2014; 8(1):49-61. PMC: 4211077. DOI: 10.1586/17474124.2014.851599. View

14.

Johnston I, Nolan J, Pattni S, Appleby R, Zhang J, Kennie S . Characterizing Factors Associated With Differences in FGF19 Blood Levels and Synthesis in Patients With Primary Bile Acid Diarrhea. Am J Gastroenterol. 2016; 111(3):423-32. DOI: 10.1038/ajg.2015.424. View

15.

Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B . Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009; 89(1):147-91. DOI: 10.1152/physrev.00010.2008. View

16.

Fu T, Choi S, Kim D, Seok S, Suino-Powell K, Xu H . Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor β-Klotho. Proc Natl Acad Sci U S A. 2012; 109(40):16137-42. PMC: 3479576. DOI: 10.1073/pnas.1205951109. View

17.

Ponziani F, Pecere S, Gasbarrini A, Ojetti V . Physiology and pathophysiology of liver lipid metabolism. Expert Rev Gastroenterol Hepatol. 2015; 9(8):1055-67. DOI: 10.1586/17474124.2015.1056156. View

18.

Akerlund J, Bjorkhem I, Angelin B, Liljeqvist L, Einarsson K . Apparent selective bile acid malabsorption as a consequence of ileal exclusion: effects on bile acid, cholesterol, and lipoprotein metabolism. Gut. 1994; 35(8):1116-20. PMC: 1375066. DOI: 10.1136/gut.35.8.1116. View

19.

Shepherd J, Packard C, Bicker S, Lawrie T, MORGAN H . Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med. 1980; 302(22):1219-22. DOI: 10.1056/NEJM198005293022202. View

20.

Walters J, Johnston I, Nolan J, Vassie C, Pruzanski M, Shapiro D . The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol Ther. 2014; 41(1):54-64. DOI: 10.1111/apt.12999. View